CAELYX (pegylated liposomal doxorubicin), cytotoxic agent - OVARIAN CANCER

No clinical benefit demonstrated in the treatment of advanced stage ovarian cancer

• CAELYX has Marketing Authorisation in advanced stage ovarian cancer in women after failure of first-line platinum-based chemotherapy.
• The new data presented in this re-assessment are not likely to demonstrate a relevant clinical benefit in the treatment of advanced stage ovarian cancer compared to:

        - available monotherapies in case of relapse resistant to platinum salts,

        - combinations used in case of relapse sensitive to platinum salts.